The Clinical Significance of Statins - Macrolides Interaction: Comprehensive Review of In vivo, Case-reports and Population Studies, Therapeutics and Clinical Risk Management

Aug 30, 2019

DOI: 10.2147/TCRM.S214938

Published in: Therapeutics and Clinical Risk Management

Publisher: Dove Medical Press

• Abu Mellal A Hussain N Said ASA

The objectives of this article were to review the mechanism and clinical significance of statins-macrolides interaction, determine which combination has the highest risk for the interaction, and identify key patients' risk factors for the interaction in relation to the development of muscle toxicity. A literature review was conducted in PubMed and Embase (1946 to December 2018) using combined terms: statins - as group and individual agents, macrolides - as group and individual agents, drug interaction, muscle toxicity, rhabdomyolysis, CYP3A4 inhibitors, and OAT1B inhibitors, with forward and backward citation tracking. Relevant English language in vivo studies in healthy volunteers, case reports, and population studies were included. The interaction between statins and macrolides depends on the type of statin and macrolide used. The mechanism of the interaction is due to macrolides' inhibition of CYP3A4 isoenzyme and OAT1B transporter causing increased exposure to statins. The correlation of this increased statin's exposure to the development of muscle toxicity could not be established, unless the patient had other risk factors such as advanced age, cardiovascular diseases, renal impairment, diabetes, and the concomitant use of other CYP3A4 inhibitors. Simvastatin, lovastatin, and to lesser extent atorvastatin are the statins most affected by this interaction. Rosuvastatin, fluvastatin, and pravastatin are not significantly affected by this interaction. Telithromycin, clarithromycin, and erythromycin are the most "offending" macrolides, while azithromycin appears to be safe to use with statins. This review presented a clear description of the clinical significance of this interaction in real practice. Also, it provided health care professionals with clear suggestions and recommendations on how to overcome this interaction. In conclusion, understanding the different characteristics of each statin and macrolide, as well as key patients' risk factors, will enable health care providers to utilize both groups effectively without compromising patient safety.

Other Researches

Levels of Vitamin D and Vitamin D Pathway Gene polymorphisms in adults: results from agriculture workers in Punjab, Pakistan

Background and aims: Worldwide low levels of vitamin D (< 30ng/dL) is prevalent and linked to bone disorders, diabetes and coronary heart disease. Deficiency in Vitamin D is a diagnostic challenge in asymptomatic individuals. The present study aimed...

Effects of Alogliptin on hypertensive chronic kidney disease with Type 2 diabetes mellitus

Background: Diabetes mellitus(DM)is a leading cause of chronic kidney disease (CKD). Theantihyperglycemic treatment options for patients with Type 2 DM are limited because of safety and tolerability concerns. Aims: To retrospectively...

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Abstract Aim. To evaluate the safety issues and adverse effects of using TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) versus TCP regimen (docetaxel, carboplatin, and trastuzumab) in older postmenopausal women with nonmetastati...

Knowledge, attitude, and practice analysis of corticosteroid use among patients: A study based in the United Arab Emirates

Background: Corticosteroids (CS) have long been known as the most powerful of all known anti-inflammatory agents. Since their introduction in 1949, they have shown pivotal role in the treatment of various serious disorders such as autoimmune disease...